ORLANDO—A novel prostate brachytherapy technique that avoids the central zone may sharply reduce periurethral prostate radiation (XBT) and significantly reduce posttreatment urinary obstruction/irritation. In addition, this approach may significantly reduce long-term urinary incontinence, according to a prospective study presented at the Genitourinary Cancers Symposium.
SAN FRANCISCO—A novel small-caliber metal stent can provide a low-risk means of palliation for severe malignant dysphagia, according to investigators who have created these stents and are now testing them in trials. The results were presented at the 2011 Gastrointestinal Cancers Symposium by Stephen Kucera, MD, of H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, where he is an interventional endoscopy fellow.
Read More ›
Patients receiving chemotherapy are at risk for reactivation of the hepatitis B virus (HBV), and this can have a significant negative impact on the outcomes, including death from liver failure. According to Emmy Ludwig, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC), New York, one-third of the world has been exposed to HBV, “making it an enormous problem.”
The US Food and Drug Administration (FDA) has approved sunitinib malate (Sutent, Pfizer) as the first anti–vascular endothelial growth factor (VEGF) therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (PNETs) in patients with unresectable, locally advanced, or metastatic disease.
To sign up for our newsletter or print publications, please enter your contact information below.
